← FDA DRUG APPROVALS

FDA NDA · NDA213690

ZILXI

minocycline

Sponsor: JOURNEY

APPLICATION
NDA213690
TYPE
NDA
ORIGINAL APPROVAL
2020-05-28
LATEST ACTION
2024-02-20
ROUTE
TOPICAL
DOSAGE FORM
AEROSOL, FOAM
MARKETING STATUS
Prescription

Products

ZILXI · ReferencePrescription
MINOCYCLINE HYDROCHLORIDE EQ 1.5% BASE · AEROSOL, FOAM · TOPICAL

Approval history

2024-02-20Manufacturing (CMC) · Supplement 9 — Label ↗AP
2020-05-28Type 5 - New Formulation or New Manufacturer · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →